Share-based Payment Arrangement, Expense in USD of Lyra Therapeutics, Inc. from Q1 2019 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Lyra Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense history and change rate from Q1 2019 to Q3 2025.
  • Lyra Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $34,000, a 98% decline year-over-year.
  • Lyra Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $3,712,000, a 41% decline year-over-year.
  • Lyra Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $6,716,000, a 14% increase from 2023.
  • Lyra Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $5,887,000, a 8.1% increase from 2022.
  • Lyra Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $5,447,000, a 97% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Lyra Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $3,712,000 $34,000 -$1,457,000 -98% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $5,169,000 $914,000 -$210,000 -19% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $5,379,000 $825,000 -$1,337,000 -62% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $6,716,000 $1,939,000 +$457,000 +31% 01 Oct 2024 31 Dec 2024 10-K 13 Mar 2025 2024 FY
Q3 2024 $6,259,000 $1,491,000 +$50,000 +3.5% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $6,209,000 $1,124,000 -$230,000 -17% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $6,439,000 $2,162,000 +$552,000 +34% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 $5,887,000 $1,482,000 -$275,000 -16% 01 Oct 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
Q3 2023 $6,162,000 $1,441,000 -$298,000 -17% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $6,460,000 $1,354,000 +$247,000 +22% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2024 Q2
Q1 2023 $6,213,000 $1,610,000 +$766,000 +91% 01 Jan 2023 31 Mar 2023 10-Q 30 Apr 2024 2024 Q1
Q4 2022 $5,447,000 $1,757,000 +$975,000 +125% 01 Oct 2022 31 Dec 2022 10-K 22 Mar 2024 2023 FY
Q3 2022 $4,472,000 $1,739,000 +$1,006,000 +137% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $3,466,000 $1,107,000 +$451,000 +69% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $3,015,000 $844,000 +$245,000 +41% 01 Jan 2022 31 Mar 2022 10-Q 12 May 2023 2023 Q1
Q4 2021 $2,770,000 $782,000 +$190,000 +32% 01 Oct 2021 31 Dec 2021 10-K 29 Mar 2023 2022 FY
Q3 2021 $2,580,000 $733,000 +$265,000 +57% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $2,315,000 $656,000 +$37,000 +6% 01 Apr 2021 30 Jun 2021 10-Q/A 02 Nov 2022 2022 Q2
Q1 2021 $2,278,000 $599,000 +$465,000 +347% 01 Jan 2021 31 Mar 2021 10-Q/A 02 Nov 2022 2022 Q1
Q4 2020 $1,813,000 $592,000 +$489,000 +475% 01 Oct 2020 31 Dec 2020 10-K 09 Mar 2022 2021 FY
Q3 2020 $1,324,000 $468,000 +$419,000 +855% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 $905,000 $619,000 +$575,000 +1307% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q2
Q1 2020 $330,000 $134,000 +$86,000 +179% 01 Jan 2020 31 Mar 2020 10-Q 11 May 2021 2021 Q1
Q4 2019 $244,000 $103,000 01 Oct 2019 31 Dec 2019 10-K 09 Mar 2021 2020 FY
Q3 2019 $49,000 01 Jul 2019 30 Sep 2019 10-Q 10 Nov 2020 2020 Q3
Q2 2019 $44,000 01 Apr 2019 30 Jun 2019 10-Q 05 Aug 2020 2020 Q2
Q1 2019 $48,000 01 Jan 2019 31 Mar 2019 10-Q 28 May 2020 2020 Q1

Lyra Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $6,716,000 +$829,000 +14% 01 Jan 2024 31 Dec 2024 10-K 13 Mar 2025 2024 FY
2023 $5,887,000 +$440,000 +8.1% 01 Jan 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
2022 $5,447,000 +$2,677,000 +97% 01 Jan 2022 31 Dec 2022 10-K 22 Mar 2024 2023 FY
2021 $2,770,000 +$957,000 +53% 01 Jan 2021 31 Dec 2021 10-K 29 Mar 2023 2022 FY
2020 $1,813,000 +$1,569,000 +643% 01 Jan 2020 31 Dec 2020 10-K 09 Mar 2022 2021 FY
2019 $244,000 01 Jan 2019 31 Dec 2019 10-K 09 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.